Chemomab Therapeutics Ltd.
A clinical-stage biotechnology company developing antibody therapies for fibro-inflammatory diseases—conditions that combine inflammation with tissue scarring. Its lead drug, nebokitug, targets a protein called CCL24 to treat liver and skin conditions like primary sclerosing cholangitis. Founded in 2011 by scientist Adi Mor, the company's name blends "chemokine" (its target protein family) with "-mab," the standard suffix for monoclonal antibodies.
Sponsored American Depositary Shares (ADS)
Granted 288.2K · Sold 336.9K
Bought 230.5K
Bought 9.8K · Sold 595.8K
Bought 12.4K · Sold 2.4K
Bought 1.8K
Bought 2.5K
Bought 1.4K
Bought 1.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| OrbiMed Israel BioFund GP Limited Partnership +1 co-filer10% owner · 3 transactions | — | 2.31Mas of Jan 2023 | 288.2K | — | 336.9K |
| Thiel Peter10% owner · 1 transaction | — | 878.0Kas of Mar 2021 | — | 230.5K | — |
| Mor George AdiChief Executive Officer, Director · 8 transactions | — | 148.1K | — | 9.8K | 595.8K |
| Cohen Neil HarrisDirector · 7 transactions | — | 35.3K | — | 12.4K | 2.4K |
| Marvin DonaldExecutive VP, CFO & COO · 7 transactions | — | 2.0Kas of Mar 2022 | — | 1.8K | — |
| Pfost Dale RChief Executive Officer, Director · 2 transactions | — | 1.8Kas of Mar 2022 | — | 2.5K | — |
| Maryles Joel MichaelDirector · 4 transactions | — | 1.4Kas of May 2022 | — | 1.4K | — |
| Darvish NissimDirector · 1 transaction | — | 300 | — | 1.2K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -675.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.